Nironovo Sr (Ropinirole)

Ropinirole, the active ingredient in Nironovo Sr, is a dopamine agonist presented as an oral dosage form for oral use. It is indicated for the management of Parkinson's disease and restless legs syndrome in adult patients.

GNH USA supplies Nironovo Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ropinirole acts on dopaminergic pathways to improve motor and sensory symptoms associated with movement disorders. - Parkinson's disease: improves motor control, reducing tremor, rigidity and bradykinesia. - Restless legs syndrome: lessens uncomfortable leg sensations and the urge to move, especially at night. - Parkinson's disease (advanced stages): helps decrease "off" periods and supports smoother symptom control.

Ropinirole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Dizziness - Somnolence - Headache - Constipation - Dry mouth

Serious or Rare Side Effects: - Hallucinations or psychosis - Impulse control disorders (e.g., compulsive gambling) - Severe hypotension or syncope - Allergic reactions such as rash or angioedema - Depression or suicidal thoughts - Sudden onset of sleep attacks

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Assess cardiovascular status: check for orthostatic hypotension and heart disease. - Monitor for impulse control disorders: watch for compulsive behaviors. - Review hepatic function: adjust use in severe liver impairment. - Avoid abrupt discontinuation: taper dose under medical supervision. - Store at room temperature: keep in the original container, protect from moisture and light.

Ropinirole can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant MAO‑B inhibitors: risk of hypertensive crisis. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase ropinirole plasma levels. - Dopamine antagonists (antipsychotics): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine): may lower ropinirole exposure. - Alcohol: can enhance central nervous system depression. - Antihypertensive agents: additive hypotensive effect may occur.